Global Small Cell Lung Cancer Market Overview
Lung cancer usually starts in the lungs, but it can spread to lymph nodes or other body organs, including the brain. Cancer from other organs, on the other hand, can travel to the lungs. Metastases are the spread of cancer cells from one organ to another. Lung cancer is divided into two types: small cell lung cancer (SCLC) and small cell lung cancer (NSCLC) (NSCLC, the more common). Both methods of treatment have different approaches. SCLC spreads (metastasizes) to other organs faster than NSCLC, despite the fact that SCLC is made up of much smaller cells. In contrast to most cases of NSCLC, SCLC can be lethal in a matter of weeks if left untreated. NSCLC also accounts for 80–85 percent of lung cancer cases. SCLC is a disease with different morphological, clinical, and molecular characteristics, as well as a significant metastatic potential that leads to a clinically dismal prognosis, whereas NSCLC does not. Because the cells resemble oats under a microscope, SCLC is often known as 'oat-cell' cancer. It usually begins in the bronchi, then spreads to other regions of the body, including the lymph nodes. The Small Cell Lung Cancer Market accounted for US$ 0.77 billion in 2020 and is estimated to be US$ 6.02 billion by 2030 and is anticipated to register a CAGR of 19.8%.
Global Small Cell Lung Cancer Market Dynamics
Introduction of immune checkpoint inhibitors
The introduction of immune checkpoint inhibitors (ICIs) into the first-line context is one of the major drivers driving market revenue growth. Small cell lung cancer accounts for 80 to 85 percent of all lung cancer cases worldwide, prompting the majority of market leaders to focus on continuous innovation of new therapies and increasing the efficacy of existing drugs. Lung cancer's position as one of the most frequent cancers, leading to a significant number of fatalities globally, is also fueling market expansion.
Increasing small cell lung cancer diagnoses
The growth of the small cell lung cancer market is assisted by an increase in the number of small cell lung cancer diagnoses and higher awareness of the disease in both developed and developing countries. This, combined with increased spending by leading businesses on research and development, as well as the presence of small cell cancer medicines in the pipelines of significant market participants, is driving worldwide market growth. One of the market's issues is the high expense of therapy for small cell lung cancer. Chemotherapy, surgery, targeted therapies, radiation therapy, and immunotherapy are all options for treating the disease, but they are all expensive.
Thus, the high cost of the treatment is expected to restrain growth of the market.
Global Small Cell Lung Cancer Market Segmentation
Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.
The Global Small Cell Lung Cancer Market is segmented based on histology, treatment, drug class distribution channel and region.
On the basis of Histology, the Global Small Cell Lung Cancer Market is segmented into Squamous Cell Carcinoma, Large Cell Carcinoma and Adenocarcinoma. Based on Treatment, the target market is segmented into Surgery, Radiation, Chemotherapy and Targeted Therapy Drugs. Based on Drug Class, the target market is segmented into Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites and PD-1/ PD-L1 Inhibitor. Based on Distribution Channel, the target market is segmented into Hospital Pharmacy, Retail Pharmacy, Others.
Regional Insights:
On region the Global Small Cell Lung Cancer Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in Asia Pacific is expected account for the largest market revenue share in small cell lung cancer market. Rising awareness about cancer and initiatives undertaken by governments in the region will encourage market growth for small cell lung cancer. Development of public healthcare centers and subsidized treatment will fuel the market growth.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2030 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
|
Market Segmentation |
By Histology- Squamous Cell Carcinoma, Large Cell Carcinoma and Adenocarcinoma By Treatment– Surgery, Radiation, Chemotherapy and Targeted Therapy Drugs By Drug Class- Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites and PD-1/ PD-L1 Inhibitor By Distribution Channel- Hospital Pharmacy, Retail Pharmacy, Others |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Small Cell Lung Cancer Market report based on histology, treatment, drug class, distribution channel and region.
Global Small Cell Lung Cancer Market, By Region:
-
-
- North America
-
- U.S.
- Canada
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- North America
-
Global Small Cell Lung Cancer Market Key Players
Key participants in small cell lung cancer market include Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. and among others. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market.
Global Small Cell Lung Cancer Market Key Issues Addressed
Key Issues Addressed
Global Small Cell Lung Cancer Market Company Profile
- Tarceva
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Avastin
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Gemzar
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Alimta
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Taxotere
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- AstraZeneca
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck KGa
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
Global Small Cell Lung Cancer Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for Small Cell Lung Cancer Strategies
- Key Questions this Study will Answer
- Market Snippet, By Histology
- Market Snippet, By Treatment
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Global Small Cell Lung Cancer Market, By Histology, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Squamous Cell Carcinoma
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Large Cell Carcinoma
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Adenocarcinoma
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Small Cell Lung Cancer Market, By Treatment, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Surgery
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Radiation
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Chemotherapy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Targeted Therapy Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Small Cell Lung Cancer Market, By Drug-Class, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Angiogenesis Inhibitor
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Epidermal Growth Factor Receptor Blocker
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Kinase Inhibitor
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Microtubule Stabilizer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Folate Antimetabolites
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- PD-1 & PD-L1 Inhibitor
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Small Cell Lung Cancer Market, By Distribution Channel, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Hospital Pharmacy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Retail Pharmacy
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Small Cell Lung Cancer Market, By Region, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Histology, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Treatment, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Drug Class, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Histology, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Treatment, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Drug Class, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Histology, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Treatment, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Drug Class, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Histology, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Treatment, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Drug Class, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Histology, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Treatment, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Drug Class, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Tarceva
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Avastin
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Gemzar
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Alimta
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Taxotere
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- AstraZeneca
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck KGa
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The Global Small Cell Lung Cancer Market is segmented based on histology, type, drug class, distribution channel, and Region.
Increasing small cell lung cancer diagnoses which is the major factor driving growth of the global market
The market in Asia Pacific is expected account for the largest market revenue share in small cell lung cancer market.
Key participants in small cell lung cancer market include Tarceva, Avastin, Gemzar, Alimta, Taxotere, AstraZeneca, Roche, Merck KGa, Nlyte, and Panduit Corp. among others.